| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Sojournix | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Sound Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $25.95M | Series C-2 | 5/24/2018 | $11.76M | $47.84M | $3.00 | Undisclosed Investors | ||||
 | Treeline Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.1B | Series A-2 | 9/3/2025 | $200.1M | $1.83B | $8.61 | Access Industries, ARCH Venture Partners, OrbiMed, GV, KKR, T. Rowe Price Associates, Ajax Health, Casdin Capital, Fidelity, Aisling Capital, Rock Springs Capital, Exor | ||||
 | Zephyr AI | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $129.71M | Series A | 3/13/2024 | $69.01M | $482.26M | $17.34 | Revolution Growth, Eli Lilly and Company, Jeff Skoll, EPIQ Capital Group | ||||
 | 23andMe | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $876.61M | Series F-1 | 12/23/2020 | $385M | $2.59B | $17.35 | GlaxoSmithKline, NewView Capital, Sequoia Capital | ||||
 | Aragen Life Sciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Arcellx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $235.48M | Series C | 4/13/2021 | $120M | $377.76M | $2.10 | Samsara BioCapital, CAM Capital, Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital, Suvretta, Terra Magnum Capital Partners, New Enterprise Associates, Novo Holdings, SR One, Takeda Ventures, LG Tech, Clough Capital | ||||
 | Arrakis Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | BigHat Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $228.41M | Series C | 7/13/2026 | $80M | $452.43M | $10.01 | Undisclosed Investors | ||||
 | Blue Earth Diagnostics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | BlueRock Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Boundless Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $756.15M | Series C | 5/16/2023 | $100M | $273.76M | $0.70 | Bayer, RA Capital Management, Sectoral Asset Management, Piper Heartland, Healthcare Capital | ||||
 | Calyxo | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.79M | Series F | 4/14/2026 | $40.1M | $658.2M | $8.82 | Ally Bridge Group, Janus Henderson Investors, Questa Capital, Avidity Partners, CRG | ||||
 | Carlsmed | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $108.89M | Series C | 2/6/2025 | $64.72M | $245.25M | $10.74 | B Capital, U.S. Venture Partners | ||||
 | City Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $239.04M | Series B | 6/8/2026 | $89.2M | $576.3M | $14.63 | Viking Global, Sofinnova Investments, Casdin Capital, NYBC Ventures, ARCH Venture Partners, Fidelity, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures | ||||
 | CleanSlate | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Concentric Analgesics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Diverge Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $52.4M | Series A-3 | 10/24/2024 | $19.08M | $264.39M | $176.74 | GV | ||||
 | Doceree | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $45.11M | Series B-2 | 9/27/2023 | $7.5M | $271.1M | $104.20 | Creaegis, Eight Roads Ventures, F-Prime Capital | ||||
 | Elixir Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Equip | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $144.89M | Series D | 9/16/2025 | $47.89M | $863.1M | $29.89 | Kerry Washington, Pledge Ventures | ||||
 | Eureka Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $130.85M | Series E | 12/16/2019 | $45M | $359.7M | $4.16 | Lyell Immunopharma, Acorn Pacific Ventures, GP Capital, Suma Venture, Harbinger Venture Capital, Yuan Capital, Majuven | ||||
 | Evidation Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $365.04M | Series E-2 | 9/23/2024 | $105M | $1.11B | $18.51 | Undisclosed Investors | ||||
 | Garner | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $298M | Series E | 5/28/2026 | $100M | $2.74B | $69.40 | Index Ventures, Kleiner Perkins, Redpoint Ventures, Thrive Capital, Sequoia Capital, Founders Fund, Kaiser Permanente Ventures | ||||